Longitudinal MRI Infrastructure · Pre-Seed · $750K

Not detecting abnormalities.
Tracking change
over time.

★ GE Healthcare acquired icometrix for Alzheimer's (Sept 2025) — the oncology tumor tracking space is now ours.

EGDAL is the vendor-agnostic middleware layer that neutralizes scanner drift between MRI machines and delivers an objective tumor growth velocity metric — turning a 90-minute manual struggle into a 60-second visual consensus.

Book a Meeting See how it works
Input — Serial MRI Scans
Multi-scanner, multi-year streams
GE · Siemens · Philips — different machines, different hospitals, different dates
↓
EGDAL Intelligence Layer
Latent Disentanglement Engine
Neutralizes hardware signatures. Aligns shifting anatomy. Physics over pixels.
Scanner-invariant · Vendor-agnostic
↓
Output → Native PACS
Objective dv/dt Growth Velocity
Delivered directly to radiologist and Tumor Board. Zero extra clicks.
60-second consensus
900+
Longitudinal brain MRI cases
IRB-approved · Maccabi KSM cloud
90→60s
Minutes saved per case
manual estimation → automated consensus
2
Live clinical POCs
Assuta · Galilee Medical Center
$3.7B
Combined addressable market
Hospital + Pharma + Insurance
★
Market validation: In September 2025, GE Healthcare acquired icometrix — our closest technology neighbor — specifically for Alzheimer's and MS monitoring. GE's acquisition validated the longitudinal MRI AI category and cleared the oncology tumor tracking space entirely for EGDAL. No competitor now owns our specific market.
Why EGDAL is Different

Not Aidoc. Not icometrix.
A different problem entirely.

Aidoc

Acute-care alerting

✕Single scan analysis only
✕No longitudinal comparison
✕No cross-scanner normalization
✕Not designed for tumor tracking
Aidoc's own product team confirmed they are not pursuing longitudinal tumor tracking.
icometrix (now GE)

Neurodegeneration monitoring

✕Alzheimer's, MS, Parkinson's only
✕Same machine, same hospital
✕Now GE-only — not vendor-agnostic
✕No oncology tumor tracking
Acquired by GE in Sept 2025. Now locked to GE scanners only.
EGDAL

Longitudinal oncology tracking

✓Compares scans across different machines
✓Works across different hospitals
✓Vendor-agnostic — GE, Siemens, Philips
✓Objective dv/dt tumor growth metric
✓Meningioma first · Glioma next
Speed & Revenue Impact

60 seconds.
Not 90 minutes.

Manual radiologist estimation 90 min
EGDAL automated consensus 60 sec
Time saving per case
89 min
saved per radiologist per scan comparison

Revenue opportunity per hospital

Avg. longitudinal MRI cases/year per hospital ~500
Time saved per case 89 min
Radiologist cost per hour (Israel) ~₪800
Annual efficiency value per hospital ~₪600K
Pharma trial contract (per trial site) $200K–500K
Insurance cost saved per misdiagnosis prevented $50K–300K
Defensibility

Three moats.
None easily replicated.

Primary Moat

The Data Moat

Exclusive IRB-approved access to 900+ multi-year, multi-scanner longitudinal brain tumor cases secured on Maccabi Healthcare's KSM cloud — with Helsinki approvals prepared under Maccabi's own institutional procedures. This dataset took three years to build. No competitor can replicate it without the same institutional relationships.

900+
exclusive cases
KSM cloud · Helsinki approved
Structural

Vendor Neutrality

Siemens and GE are structurally disincentivized to optimize competitors' scanners. EGDAL is the vendor-agnostic "Switzerland" — the only player that benefits from every scanner in the room.

Technical

Physics-Informed Edge

Aidoc compares pixels within a single scan. icometrix compares scans on the same machine. EGDAL neutralizes hardware drift across different machines — a fundamentally harder and unclaimed physics problem.

Market Opportunity

Three revenue channels.
One unclaimed market.

Hospital IT & Clinical
$2.5B · 8% CAGR
Pharma & Clinical Trials
$1.2B · 7.8% CAGR
Insurance / HMO
Emerging
✦ Insurance channel: $50K–$300K saved per misdiagnosis prevented · Maccabi is natural first partner
Clinical Traction

Real workflows.
Real champions.

Dr. Michal Gindi
Assuta Medical Center
Tier-1 workflow specifications defined in direct collaboration. Product-market fit confirmed.
Dr. Danny Paz
Galilee Medical Center · Clinical Lead
Clinical and technical validation achieved. Active POC running in live hospital environment.
Dr. Daphna Ben Basat
Ichilov Medical Center
"Few companies are doing what EGDAL does." Open evaluation pipeline pending Beta deployment.
The Team

Built to separate
deep-tech from hospital IT.

Gil Rapoport
Founder & CEO
Secured the exclusive Maccabi data moat, 4 IRB/Helsinki approvals, and closed 3 clinical partnerships (ARC, Assuta, Galilee).
CTO · Co-Founder
Deep-Tech Engineering Lead
15–20% equity reserved. Currently in advanced discussions with top-tier candidates to close alongside this round.
Lior Gorodisky
Chief Scientist
Computer Vision Post-Doc, Weizmann Institute. Leading the physics-informed AI and Latent Disentanglement engine.
Itamar Grutman
Lead Integration Engineer
Designing the Zero-Click PACS architecture and UI deployment based on successful POC.
Dr. Danny Paz
Clinical Lead
Head of Galilee Medical Center POC. Bridges engineering and the reading room.
The Raise

$750K Pre-Seed Sprint.
Floor valuation. Beta next.

Raising via SAFE at a $4.5M valuation cap — 7-month sprint to algorithm lock, PACS integration, and live Beta at Assuta and Nahariya.

Raise
$750K
SAFE instrument
Valuation Cap
$4.5M
Pre-Seed entry
Post-Beta Seed
$15–20M
Target valuation
Book a Meeting with Gil →